Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of lampalizumab in geographic atrophy
2012-000578-41Phase 2Terminated
- Sponsor
- Genentech
- Start
- Sep 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lampalizumab in age-related macular degeneration (AMD), sponsored by Genentech. Primary endpoint: Primary safety endpoint. Started Sep 2012; status: terminated.
02
Drugs
lampalizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2012-000578-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000578-41.